This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Lyme neuroborreliosis

Authoring team

  • approximately 15% get neurological manifestations (neuroborreliosis), which usually occur within four weeks of the initial illness and resolve over 3 months. It is the most common complication of lyme disease in UK and may include (1,2):
    • meningoradiculoneuritis (Bannwarth's syndrome)
    • meningitis
    • cranial neuritis - usually VII, with palsy - very hard to distinguish from Bell's palsy
      • may be bilateral in up to 25% of individuals (3)
      • neuroborreliosis in children commonly manifests as facial nerve palsy, in contrast to adults who typically present with radiculoneuritis and lymphocytic CSF leocytosis (3)
      • Lyme radiculitis may present with signs resembling disc herniation
    • radicular neuritis (radiculoneuritis)
      • Lyme radiculitis may present with signs resembling disc herniation
        • pain is neuropathic, and dermatomal in distribution, while sensory defects and paresis may occur
    • parenchymal brain involvement is extremely rare
      • sporadic cases of chronic encephalitis or encephalomyelitis owing to Lyme borreliosis have been reported
      • cerebrovascular events resulting from CNS vasculitis have been associated with Lyme borreliosis, based on brain biopsy or intrathecal synthesis of anti-Borrelia antibodies, responding to antibiotic therapy

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.